Black Diamond Therapeutics (BDTX) has been downgraded from Strong Buy to Buy due to a slower-than-expected start of phase 3 trials for its lung cancer drug silevertinib, targeting non-classical EGFR mutations in NSCLC. Despite this, phase 2 results showed a strong response rate, especially in brain metastases, outperforming current treatments. Key upcoming catalysts include updated phase 2 data and FDA feedback expected in late 2026. BDTX remains financially strong with funding secured through mid-2028 and is also expanding its pipeline into glioblastoma treatment.
Black Diamond Therapeutics faces a downgrade due to delayed trial results. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 03, 2026 23:21 WIB: out of 150 priced US health-sector stocks, 118 rose and 32 fell. Notable movers include IOVA at USD 8.63 (+7.61%), ERAS at USD 14.94 (+6.30%), and WGS at USD 68.06 (+6.19%) with 100% buy order activity on Pluang for WGS.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
The Hospitality Show, a key event for hotel operations, will return to Las Vegas from March 27–29, 2028, at the Las Vegas Convention Center. This marks a return to its original location and an earlier spring date, chosen to better align with hospital...
FarmQA and Planet Labs have partnered to develop AI-powered agronomic tools for enterprise agriculture, starting with a sugar beet yield estimation model. This model combines Planet's satellite imagery with FarmQA's field-verified agronomic data to p...
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...
